CN117618283B - Oil-control anti-acne facial cleanser composition, application thereof and gel - Google Patents
Oil-control anti-acne facial cleanser composition, application thereof and gel Download PDFInfo
- Publication number
- CN117618283B CN117618283B CN202311691564.XA CN202311691564A CN117618283B CN 117618283 B CN117618283 B CN 117618283B CN 202311691564 A CN202311691564 A CN 202311691564A CN 117618283 B CN117618283 B CN 117618283B
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- sodium
- acne
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003255 anti-acne Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000001815 facial effect Effects 0.000 title claims abstract description 14
- 244000025272 Persea americana Species 0.000 claims abstract description 16
- 235000008673 Persea americana Nutrition 0.000 claims abstract description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 11
- 229940049964 oleate Drugs 0.000 claims abstract description 11
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 24
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 12
- 229930182478 glucoside Natural products 0.000 claims description 12
- -1 malto-oligosaccharide glucoside Chemical class 0.000 claims description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 10
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229920006037 cross link polymer Polymers 0.000 claims description 6
- 150000008131 glucosides Chemical class 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 229940079988 potassium cocoyl glycinate Drugs 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- 210000002374 sebum Anatomy 0.000 abstract description 19
- 206010000496 acne Diseases 0.000 abstract description 18
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 17
- 230000028327 secretion Effects 0.000 abstract description 14
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 239000004519 grease Substances 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 16
- 239000000284 extract Substances 0.000 description 15
- 210000001732 sebaceous gland Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WIBFFTLQMKKBLZ-SEYXRHQNSA-N n-butyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCC WIBFFTLQMKKBLZ-SEYXRHQNSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 4
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229940104261 taurate Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- KTYVHLCLTPLSGC-UHFFFAOYSA-N amino propanoate Chemical compound CCC(=O)ON KTYVHLCLTPLSGC-UHFFFAOYSA-N 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940109850 royal jelly Drugs 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 2
- 240000003690 Callicarpa japonica Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- 235000015456 Japanese beauty berry Nutrition 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- 244000179970 Monarda didyma Species 0.000 description 2
- 235000010672 Monarda didyma Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229940114496 olive leaf extract Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 235000015206 pear juice Nutrition 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229940084038 salix alba bark extract Drugs 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 244000307888 Acanthus ebracteatus Species 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001237160 Kallima inachus Species 0.000 description 1
- 240000003664 Maclura cochinchinensis Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 235000010337 Rosa dumalis Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
The application belongs to the technical field of cosmetic production, and discloses an oil-control anti-acne facial cleanser composition which comprises the following components in percentage by mass of 0.01-5: 0.1 to 25: the oil-control anti-acne facial cleanser comprises 0.001-1 part of sodium hyaluronate HA60, PEG-20 triisostearate, butyl avocado oleate and 69-99.889 parts of gel carrier, wherein the oil-control anti-acne facial cleanser can deeply clean skin grease and is favorable for inhibiting sebum secretion so as to achieve the effects of controlling oil and resisting acne.
Description
Technical Field
The invention relates to the technical field of cosmetic production, in particular to an oil-control anti-acne facial cleanser composition, application thereof and gel.
Background
The grease on the skin surface is mainly sebum secreted by sebaceous glands, and the secreted sebum reaches the skin surface along a follicular duct to finish the seborrhea. However, due to the special structure of the follicular orifice, follicular orifice corner plugs are easily formed by hyperkeratosis, normal sebum discharge is blocked, micro-acne is formed, meanwhile, acne shortrod bacterins are greatly proliferated, and visible acne-like symptoms such as nodules are formed by further development. The role of sebaceous glands in secreting sebum is mainly controlled by hormonal stimulation, with 5 a-reductase being one of the key hormones for acne production. Therefore, the preparation can inhibit hormone to stimulate sebaceous glands to generate sebum, dissolve follicular micro-acne, and make deep skin clean, thereby being beneficial to relieving acne and acnes. The effective treatment measures of the skin beauty center for acne are to remove the acne content in hair follicles by various modes, and finally to disinfect, anti-inflammatory, care and the like again so as to restore the skin to a healthy state.
The Chinese patent 202210982728.3 discloses a mild low-sensitivity moisturizing acne-removing gel and a preparation method thereof, wherein the gel comprises the following components in percentage by weight: 0.5-2% of salicylic acid and 0.5-6% of polyhydroxycarboxylic acid, wherein the solubilizer is selected from poloxamer.
In the mild and low-sensitivity moisturizing acne-removing gel prepared by the scheme, salicylic acid shallow layers are stripped, and excessive oil is prevented and treated, and closed mouth and acne (blackhead and whitehead) are treated; azelaic acid is anti-inflammatory and antibacterial, and is used for preventing and treating inflammatory red swelling type acnes and acne marks; the polyhydroxycarboxylic acid promotes biosynthesis of glycosaminoglycans or collagen in the skin, and plays a role in moisturizing, relieving and repairing. The proposal utilizes the specific proportion of the three components to make the effects complementary, synergize and moisten the skin mildly and lowly, and simultaneously has high-efficiency and comprehensive prevention and treatment effects on different types of acnes, and has excellent acne-removing effect.
Chinese patent 202010455320.1 discloses an oil-control acne-removing composition which comprises the following components: 5-10 parts of lactobacillus/pear juice fermentation product filtrate, 2-4 parts of white willow bark extract, 5-14 parts of cortex phellodendri extract, 5-12 parts of cordate houttuynia extract, 3-10 parts of Japanese beautyberry extract, 1-6 parts of matrine, 3-14 parts of centella asiatica extract, 2-6 parts of radix scutellariae extract, 0.1-4 parts of royal jelly oil control composition, 0.5-2 parts of olive leaf extract, 2-6 parts of peony root extract, 1-2 parts of mountain branchlet and 0.5-3 parts of bergamot leaf extract; the royal jelly oil control composition comprises the following components in percentage by weight of 80-82:4-8: 4-6:4-8 of 1, 3-butanediol, 10-hydroxydecanoic acid, sebacic acid and 1, 10-decanediol.
According to the scheme, lactobacillus/pear juice fermentation product filtrate with pore dredging effect and white willow bark extract, cortex phellodendri extract with anti-inflammatory effect, herba houttuyniae extract with anti-inflammatory effect, japanese beautyberry extract with skin antioxidation and sebum oxidation prevention function, matrine with antimicrobial activity, centella asiatica extract for relieving skin sensitivity, elastase-inhibiting, free radical-eliminating and antioxidation baical skullcap root extract, a royal jelly oil control composition for reestablishing sebum balance of acne-prone skin, an olive leaf extract with ultraviolet-proof effect, a peony root extract with inhibition effect on metalloprotease and elastase, a mountain-cloth dead leaf extract capable of controlling grease secretion frequency, and bergamot leaf extract with moisturizing and antioxidation effect are adopted, and the oil control acne removal composition realizes anti-acne maintenance stability and effective prevention of vaccinia repetition through compounding of the substances; at the same time, it can be seen that this solution does not achieve the anti-acne objective from the standpoint of inhibition of 5α -reductase.
Chinese patent 202110940452.8 discloses an oil control composition containing a plant active ingredient comprising a component that inhibits 5α -reductase, wherein the component employed that inhibits 5α -reductase comprises a bioflavonoid, preferably a plant acanthus (Maclura cochinchinensis) leaf extract.
According to the scheme, bioflavonoids, dog rose hip extracts and sarcosine are combined to form an oil control scheme, sebum secretion is regulated from two targets of inhibiting 5 a-reductase and sebaceous gland differentiation, meanwhile, skin is relieved, skin pressure is reduced, and the activity of sebaceous cells is reduced, so that the aim of controlling oil more efficiently is achieved.
The problem that this scheme needs to solve: a novel oil-controlling anti-acne composition capable of reducing excessive sebum secretion is developed.
Disclosure of Invention
The invention aims to provide an oil-control anti-acne cleansing composition, which has the capabilities of water locking, moisture preservation, oxidation resistance, inflammation resistance, oil control and the like, and the oil-control anti-acne cleansing gel can inhibit the expression of 5 a-reductase, further reduce sebum secretion, effectively deeply clean sebum and other secretions in facial hair follicles, and reduce hair follicle blockage.
In order to achieve the aim, the application discloses an oil-control anti-acne facial cleanser composition which comprises, by mass, sodium hyaluronate HA60, PEG-20 triisostearate and butyl avocado oleate, wherein the mass ratio of the sodium hyaluronate HA60 to the PEG-20 triisostearate to the butyl avocado oleate is 0.01-5: 0.1 to 25:0.001 to 1.
Preferably, the mass ratio of the sodium hyaluronate HA60, the PEG-20 glycerol triisostearate and the butyl avocado oleate is 0.01-2: 0.1 to 5:0.001 to 0.2.
In addition, the application also discloses application of the oil-control anti-acne facial cleanser composition as an oil-control anti-acne facial cleanser active ingredient in daily chemicals.
In addition, the application also discloses an oil-control anti-acne facial cleanser, which comprises, by mass, 0.111-31 parts of the oil-control anti-acne facial cleanser and 69-99.889 parts of a gel carrier.
Preferably, the gel carrier comprises the following components in parts by mass:
Preferably, the gel carrier comprises the following components in parts by mass:
the beneficial effects of the application are as follows:
The sodium hyaluronate can form a layer of film on the surface of skin to lock moisture, so that the skin is kept moist, moisture loss is prevented, and the elasticity and luster of the skin are maintained; meanwhile, the sodium hyaluronate has good moisturizing and repairing effects on skin, can promote the growth and repairing of cells, improve the rough and dry skin and other problems, enhance the nutrition absorption capacity of skin cells, promote the generation of collagen and elastic fibers, improve the elasticity and compactness of the skin, reduce wrinkles and fine lines and effectively resist aging. The sodium hyaluronate can also absorb ultraviolet rays to prevent the skin from being damaged by the ultraviolet rays, and meanwhile, the sodium hyaluronate can influence the transparency of the stratum corneum to increase the luster and the transparency of the skin;
The PEG-20 triisostearate can form a protective film, prevent water loss, keep skin moist, and meanwhile, the PEG-20 triisostearate is an excellent emulsifier, and can uniformly mix water and oil, so that the cosmetic is more stable. And the PEG-20 glycerol triisostearate has cleaning and makeup removing effects and can be used in a face cleaning product or a makeup removing product. PEG-20 triisostearate can also improve the luster and transparency of the skin, and make the skin more attractive and attractive. PEG-20 triisostearate can relieve skin irritation of cosmetics and reduce skin allergy occurrence probability;
The butyl avocado oleate provided by the application can be quickly absorbed by skin, a protective layer is formed on the skin, moisture is locked, and the moisture retention capacity of the skin is enhanced, so that the skin is moistened and soft. Meanwhile, the avocado butyl oleate contains abundant vitamin E and various antioxidant substances, can help skin resist free radical attack, reduces oxidative damage, and is beneficial to skin health and luster. The avocado butyl oleate can promote the growth and repair of skin cells, improve the problems of skin texture, darkness and the like, and has good relieving effects on the problems of skin inflammation, sensitivity and the like. The avocado butyl oleate can also permeate into deep layers of skin, regulate skin grease balance and shrink pores, thereby improving skin texture and enabling skin to be smoother and finer. In addition, the avocado butyl oleate is a stable grease component, has a longer shelf life and can prolong the service life of cosmetics.
The application realizes the effective inhibition of the expression of 5 a-reductase by compounding the substances and using the substances together with gel, thereby reducing sebum secretion, and the oil-controlling anti-acne cleansing gel can effectively clean sebum and other secretions in the hair follicles of the face deeply and reduce the blockage of the hair follicles by the synergistic effect of the substances.
Detailed Description
The present invention will be described more fully hereinafter with reference to the accompanying drawings, in which specific conditions, either conventional or manufacturer-suggested, are not explicitly stated. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Before describing the examples in detail, the following description is made of the information of the raw materials used in the examples:
sodium hyaluronate HA60: purchased from biotechnology limited company under the east of shan through the sky;
PEG-20 glycerol triisostearate: purchased from irinotecan;
butyl avocado oleate: purchased from Laboratoires Expanscience;
Potassium cocoyl glycinate: purchased from Changsha Puji Biotech Co., ltd;
glycerol: purchased from taco brown chemical (Zhangjihong Kong) Co., ltd;
sodium cocoyl methyl taurate: zhengzhou ren Ming chemical products Co., ltd;
Sodium cocoamidopropionate: gano chemical industry Co., ltd;
Sodium PCA: nanjing Baimuda Biotechnology Co., ltd;
Trehalose: zhejiang Tianqi bioengineering Co., ltd;
p-hydroxyacetophenone: shaanxi Saen Biotech Co., ltd;
Sodium lauroyl oat amino acid: shanxi Shangcheng Biotech Co., ltd;
maltooligosaccharide glucoside: shaanxi, shengzhi Biotech Co., ltd;
Xylitol-based glucoside: peptide loving biotechnology (western) limited;
acrylic/stearyl polyether-20 methacrylate crosslinked polymer: beijing Huamei reciprocal biochemical engineering, model Carbop Smart C-F;
potassium hydroxide: henan He Yu Jia chemical products Co., ltd;
1, 2-hexanediol: gano chemical industry Co., ltd;
examples 1 to 6
Preparation of gel carrier:
step 1: firstly, mixing 8 parts of potassium cocoyl glycinate, 5 parts of glycerol, 2 parts of sodium cocoyl methyl taurate, 1.5 parts of sodium cocoyl amino propionate, 1.5 parts of PCA sodium, 0.75 part of trehalose, 0.6 part of p-hydroxyacetophenone, 0.2 part of lauroyl oat amino acid sodium, 0.2 part of maltooligosaccharide glucoside and 0.15 part of xylitol-based glucoside with part of water, heating, stirring and dissolving for later use;
step 2: mixing part of water with 2 parts of acrylic acid (ester) or stearyl alcohol polyether-20 methacrylate cross-linked polymer uniformly, adding into the solution in the step 1, and stirring uniformly;
step 3: mixing part of water with 0.5 part of potassium hydroxide uniformly, adding into the solution, and stirring uniformly;
step 4: adding 0.6 part of1, 2-hexanediol into the solution, and fully and uniformly stirring.
The formula of the oil-control anti-acne facial cleanser composition and the gel are shown in table 1, and the formula is that only the mass parts of water in a gel carrier are changed:
TABLE 1
Example 7
Substantially the same as in example 1, except that the gel carrier was prepared by:
Step 1: firstly, mixing 7 parts of potassium cocoyl glycinate, 4 parts of glycerol, 1 part of sodium cocoyl methyl taurate, 1 part of sodium cocoyl aminopropionate, 1 part of PCA sodium, 0.5 part of trehalose, 0.1 part of p-hydroxyacetophenone, 0.1 part of lauroyl oat amino acid sodium, 0.1 part of maltooligosaccharide glucoside and 0.1 part of xylitol-based glucoside with part of water, heating, stirring and dissolving for later use;
Step 2: mixing part of water with 1 part of acrylic acid (ester) or stearyl alcohol polyether-20 methacrylate cross-linked polymer uniformly, adding into the solution in the step 1, and stirring uniformly;
Step 3: mixing part of water with 0.1 part of potassium hydroxide uniformly, adding into the solution, and stirring uniformly;
step 4: adding 0.4 part of1, 2-hexanediol into the solution, and fully and uniformly stirring.
Example 8
Substantially the same as in example 1, except that the gel carrier was prepared by:
Step 1: firstly, mixing 9 parts of potassium cocoyl glycinate, 6 parts of glycerol, 3 parts of sodium cocoyl methyl taurate, 2 parts of sodium cocoyl aminopropionate, 2 parts of PCA sodium, 1 part of trehalose, 1 part of p-hydroxyacetophenone, 1 part of sodium lauroyl oat amino acid, 1 part of maltooligosaccharide glucoside and 1 part of xylitol-based glucoside with part of water, heating, stirring and dissolving for later use;
Step 2: mixing part of water with 3 parts of acrylic acid (ester) or stearyl alcohol polyether-20 methacrylate cross-linked polymer uniformly, adding into the solution in the step 1, and stirring uniformly;
Step 3: mixing part of water with 0.8 part of potassium hydroxide uniformly, adding into the solution, and stirring uniformly;
Step 4: adding 1 part of 1, 2-hexanediol into the solution, and fully and uniformly stirring.
Comparative examples 1 to 3
A composition gel having a formulation as shown in table 2:
The formulation is shown in Table 2:
TABLE 2
Comparative example 4
Substantially the same as in example 4, except that sodium hyaluronate was replaced with the same parts by weight of sodium polyglutamate.
Comparative example 5
Substantially the same as in example 4, except that the same parts by weight of PEG-6 caprylic/capric glyceride was used instead of PEG20 triisostearate.
Comparative example 6
Substantially the same as in example 4, except that the same mass fraction of butyl oleate was used instead of butyl avocado oleate.
Performance test:
irritation evaluation:
The gel prepared in examples 1 to 8 was taken as a sample, and skin irritation test for skin irritation/corrosiveness test showed that the gel prepared in examples 1 to 8 had no irritation to skin. And the invention has no photosensitive reaction through skin phototoxicity test.
Spot-mapping experiments:
The gel prepared in examples 1-8 was taken as a sample, and the results of the skin patch test on human bodies showed that no adverse reaction occurred.
Sample inhibition intracellular lipid synthesis assay:
lipid synthesis is regulated primarily by the endocrine system, while androgens (testosterone and DHT) are the primary factors affecting sebum secretion, which regulate sebaceous gland differentiation, proliferation and sebum synthesis and secretion; the 5 alpha-reductase can promote the generation of DHT, so as to promote the synthesis of lipid;
Brief description of the method: the project mainly takes SZ95 sebaceous gland cells as a research object, and selects proper induction conditions and proper male standard substances to evaluate the inhibition effect of the invention on the sebum secretion of the cells so as to judge the oil control effect.
Verification of the ability of the samples to inhibit intracellular lipid synthesis: SZ95 sebaceous gland cells were inoculated into 6-well cell culture plates, cultured for 48h at 2x10 5 per well, and medium containing the gel prepared in example 2 was added, and the concentration was determined to be 0.01%,0.04%,0.08% according to the maximum drug concentration at which the gel had no significant effect on cell proliferation.
Meanwhile, berberine hydrochloride is used for replacing gel to prepare a culture medium as a positive control group, and the concentration of the berberine hydrochloride is 0.08%;
deionized water is used for replacing berberine hydrochloride to serve as a blank control group;
After further culturing for 48h, digestion was terminated with 0.25% trypsin containing 0.02% EDTA, and the digestion was stopped with 10% calf serum in medium, washed 2 times with PBS, single cell suspensions (in PBS) were prepared, nile red fluorescent dye was added at a final concentration of 10ng/mL, incubated at room temperature for 15min, filtered with a 300 mesh nylon filter, 10000 cells in each sample were detected on a flow cytometer, the average fluorescence intensity of each cell was calculated, and 3 parallel wells were set for each concentration sample.
Discussion of results: compared with the control group, the three concentration samples and the positive control have the effect on the lipid synthesis in SZ95 cells, wherein the effect is reduced by 2.7% in the 0.01% group, 18.1% in the 0.04% group and 30.3% in the 0.08% group; the positive control group decreased by 41.7%, which indicates that the sample group can effectively inhibit the synthesis of lipid in SZ95 sebaceous gland cells.
Comparison of the ability to inhibit intracellular lipid synthesis between examples 1-6: SZ95 (human sebaceous gland cells) cells were inoculated into 6-well cell culture plates, each well was incubated for 48 hours at 2x10 5, and the concentrations of the gels in the above culture media were 0.08% each, respectively, containing the gel prepared in example 1, the gel prepared in example 2, the gel prepared in example 3, the gel prepared in example 4, the gel prepared in example 5, and the gel prepared in example 6.
After further culturing for 48h, digestion was terminated with 0.25% trypsin containing 0.02% EDTA, and the digestion was stopped with 10% calf serum in medium, washed 2 times with PBS, single cell suspensions (in PBS) were prepared, nile red fluorescent dye was added at a final concentration of 10ng/mL, incubated at room temperature for 15min, filtered with a 300 mesh nylon filter, 10000 cells in each sample were detected on a flow cytometer, the average fluorescence intensity of each cell was calculated, and 3 parallel wells were provided for each sample.
Discussion of results: examples 1-6 were compared to each other for effects on lipid synthesis in SZ95 cells, 19.4% decrease in example 1, 32.5% decrease in example 2, 18.1% decrease in example 3, 19.9% decrease in example 4, 26.3% decrease in example 5, and 18.7% decrease in example 6. From the results, it can be demonstrated that the gel of example 2 has the most remarkable effect of inhibiting the synthesis of lipid in SZ95 sebaceous gland cells.
Comparison of the ability of example 2 to comparative examples 1-3 to inhibit intracellular lipid synthesis: SZ95 (human sebaceous gland cells) cells were inoculated into 6-well cell culture plates, each well was incubated for 48 hours at 2x10 5, and the gel prepared in comparative example 1, comparative example 2, comparative example 3, and example 2 were added, respectively, at a concentration of 0.08% in the above medium. After further culturing for 48h, digestion was terminated with 0.25% trypsin containing 0.02% EDTA, and the digestion was stopped with 10% calf serum in medium, washed 2 times with PBS, single cell suspensions (in PBS) were prepared, nile red fluorescent dye was added at a final concentration of 10ng/mL, incubated at room temperature for 15min, filtered with a 300 mesh nylon filter, 10000 cells in each sample were detected on a flow cytometer, the average fluorescence intensity of each cell was calculated, and 3 parallel wells were provided for each sample.
Discussion of results: comparative examples 1-3 have 11.7% lower effect on SZ95 intracellular lipid synthesis compared to example 2, 13.9% lower in comparative example 1, and 10.3% lower in comparative example 3; whereas example 2 decreased by 29.1%, it was demonstrated that the gel inhibition effect of lipid synthesis in SZ95 sebaceous gland cells was decreased in the absence of any of sodium hyaluronate HA60, PEG-20 triisostearate and butyl avocado oleate.
Comparison of the ability of example 2 to comparative examples 4-6 to inhibit intracellular lipid synthesis: SZ95 (human sebaceous gland cells) cells were inoculated into 6-well cell culture plates, each well was incubated for 48 hours at 2x10 5, and the gel prepared in comparative example 4, comparative example 5, comparative example 6, and example 2 were added, respectively, at a concentration of 0.08% in the above medium.
After further culturing for 48h, digestion was terminated with 0.25% trypsin containing 0.02% EDTA, and the digestion was stopped with 10% calf serum in medium, washed 2 times with PBS, single cell suspensions (in PBS) were prepared, nile red fluorescent dye was added at a final concentration of 10ng/mL, incubated at room temperature for 15min, filtered with a 300 mesh nylon filter, 10000 cells in each sample were detected on a flow cytometer, the average fluorescence intensity of each cell was calculated, and 3 parallel wells were provided for each sample.
Discussion of results: comparative examples 4-6 have 12.5% lower effect on SZ95 intracellular lipid synthesis compared to example 2, 11.2% lower in comparative example 4, 11.1% lower in comparative example 5, and 11.1% lower in comparative example 6; while the decrease in the group of example 2 was 31.5%, it was revealed that the inhibition of the synthesis of lipid in SZ95 sebaceous gland cells by the gel was decreased by replacing any of the above components with components close to sodium hyaluronate HA60, PEG-20 glycerol triisostearate, and butyl avocado oleate.
From the results of the performance test, the inhibition capability of the gel on intracellular lipid synthesis is obviously reduced after the gel prepared by compounding sodium hyaluronate HA60, PEG-20 glycerol triisostearate and avocado butyl oleate is lack or any component is replaced by similar substances.
Oil control efficacy human body evaluation:
The safety evaluation of the sample before the experiment passes through cosmetic safety technical Specification (2022 edition) to confirm that the sample is safe and has no side reaction.
The experiment was divided into a positive control group, a blank group and a sample group, wherein the average grease secretion amount of volunteers changes with time after using the product, the sample group uses the gel prepared in example 2, the control group uses an equivalent amount of berberine hydrochloride solution with concentration of 0.2%, and the blank group uses an equivalent amount of deionized water.
Washing off with clear water after 15min, wherein the sebum secretion of the volunteers in the control group is reduced by 30.11% compared with that in the blank group, and the sebum secretion of the volunteers in the sample group is reduced by 25.32% compared with that in the blank group; after 6 hours, the control group and the sample group were reduced by 14.97% and 12.36% respectively from the blank group, and it was found that the control group and the sample group were significantly different from the blank group. Therefore, the sample group can effectively control oil and has anti-acne effect.
Claims (2)
1. The oil-control anti-acne cleansing gel is characterized by comprising, by mass, 0.111-31 parts of oil-control anti-acne cleansing composition and 69-99.889 parts of gel carrier;
The oil-control anti-acne facial cleanser composition comprises sodium hyaluronate HA60, PEG-20 glycerol triisostearate and butyl avocado oleate, wherein the mass ratio of the sodium hyaluronate HA60 to the PEG-20 glycerol triisostearate to the butyl avocado oleate is 0.01-5: 0.1 to 25:0.001 to 1;
The gel carrier comprises the following components in parts by mass:
5-10 parts of potassium cocoyl glycinate;
2-8 parts of glycerol;
1-3 parts of acrylic acid (ester)/stearyl alcohol polyether-20 methacrylate cross-linked polymer;
1-3 parts of cocoyl methyl taurine sodium;
1-3 parts of sodium cocoamidopropionate;
1-3 parts of PCA sodium;
0.5-1 part of trehalose;
0.1 to 1 part of potassium hydroxide;
0.1-1 part of 1, 2-hexanediol;
0.1 to 1 part of p-hydroxyacetophenone;
0.1 to 1 part of lauroyl oat amino acid sodium;
0.1-1 part of malto-oligosaccharide glucoside;
0.1 to 1 part of xylitol-based glucoside;
the water is supplemented to 69-99.889 parts.
2. The oil-control anti-acne cleansing gel according to claim 1, wherein the gel carrier comprises the following components in parts by mass:
7-9 parts of potassium cocoyl glycinate;
4-6 parts of glycerol;
1-3 parts of acrylic acid (ester)/stearyl alcohol polyether-20 methacrylate cross-linked polymer;
1-3 parts of cocoyl methyl taurine sodium;
1-2 parts of sodium cocoamidopropionate;
1-2 parts of PCA sodium;
0.5-1 part of trehalose;
0.1 to 0.8 part of potassium hydroxide;
0.4-1 part of 1, 2-hexanediol;
0.1 to 1 part of p-hydroxyacetophenone;
0.1 to 1 part of lauroyl oat amino acid sodium;
0.1-1 part of malto-oligosaccharide glucoside;
0.1 to 1 part of xylitol-based glucoside;
the water is supplemented to 69-99.889 parts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311691564.XA CN117618283B (en) | 2023-12-11 | 2023-12-11 | Oil-control anti-acne facial cleanser composition, application thereof and gel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311691564.XA CN117618283B (en) | 2023-12-11 | 2023-12-11 | Oil-control anti-acne facial cleanser composition, application thereof and gel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117618283A CN117618283A (en) | 2024-03-01 |
CN117618283B true CN117618283B (en) | 2024-06-14 |
Family
ID=90018131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311691564.XA Active CN117618283B (en) | 2023-12-11 | 2023-12-11 | Oil-control anti-acne facial cleanser composition, application thereof and gel |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117618283B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115154375A (en) * | 2022-08-18 | 2022-10-11 | 陕西慧康生物科技有限责任公司 | Stable cleaning composition with repairing and relieving effects |
CN115487100A (en) * | 2022-09-23 | 2022-12-20 | 诺斯贝尔化妆品股份有限公司 | Cosmetic composition and cosmetic with effects of controlling oil and refining pores |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150116301A (en) * | 2014-04-07 | 2015-10-15 | 코스맥스 주식회사 | Cleansing cosmetic composition comprising Yucca Schidigera, Psoralea corylifolia L. and Ceramium kondoi for inhibition of sebum secretion and alleviating skin irritation |
CN115670968B (en) * | 2022-10-31 | 2023-08-25 | 梅晔生物医药股份有限公司 | Composition with anti-inflammatory and allergy-relieving effects and daily chemical product |
-
2023
- 2023-12-11 CN CN202311691564.XA patent/CN117618283B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115154375A (en) * | 2022-08-18 | 2022-10-11 | 陕西慧康生物科技有限责任公司 | Stable cleaning composition with repairing and relieving effects |
CN115487100A (en) * | 2022-09-23 | 2022-12-20 | 诺斯贝尔化妆品股份有限公司 | Cosmetic composition and cosmetic with effects of controlling oil and refining pores |
Also Published As
Publication number | Publication date |
---|---|
CN117618283A (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111297754B (en) | Day-tightening oil-control essence and preparation method thereof | |
CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
CN105434211A (en) | Moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition and preparation method thereof | |
JP4425163B2 (en) | Anti-aging cosmetics | |
CN111388376A (en) | Jasmine herbal anti-allergy soothing mask and preparation method thereof | |
CN112472653A (en) | Acne-removing aloe gel and preparation method thereof | |
CN114469822A (en) | Acne-removing repairing cream and preparation method thereof | |
CN113491651A (en) | Soothing and repairing mask essence containing camellia extract and preparation method and application thereof | |
CN110693778A (en) | Face cream and production process thereof | |
CN111956585B (en) | Carnosine freckle removing liquid and preparation method thereof | |
CN117618283B (en) | Oil-control anti-acne facial cleanser composition, application thereof and gel | |
CN107496282A (en) | A kind of tea facial mask containing EGCG and preparation method thereof | |
CN112137933A (en) | Composition with whitening, moisturizing and repairing effects | |
CN111840203B (en) | Anti-aging moisturizing face cream | |
CN115227608A (en) | Repair moisturizing spray and preparation method thereof | |
CN115025009A (en) | Multifunctional Mannich root ice river mud space sand-shaped clean mud film and preparation method thereof | |
CN106806254A (en) | A kind of exfoliated yellow peach ferment facial mask and preparation method thereof | |
TW202106325A (en) | Use ofrosa rugosaextract for manufacturing composition inhibiting skin aging | |
CN113069377A (en) | Anti-aging face cream and preparation method thereof | |
CN112999106A (en) | Natural moisturizing liquid and preparation method thereof | |
CN111773156A (en) | Hand cream with moisturizing effect and preparation method thereof | |
CN117338626B (en) | Anti-aging whitening and moisturizing composition and preparation method thereof | |
CN106974843A (en) | A kind of exfoliated apple ferment facial mask and preparation method thereof | |
CN111803430A (en) | Face-beautifying cream and preparation method thereof | |
CN117752581A (en) | Composition for improving acne muscles and relieving and moisturizing skin and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |